Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Ixazomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 19/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 7/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 7/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 7/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 7/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 6/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 6/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 6/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 6/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 6/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 6/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 6/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 6/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 6/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 6/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 6/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 6/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 6/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 6/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ixazomib SCHEMBL3742758 | 1.00 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL18088836 | 1.00 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL3753435 | 0.92 | PSMB5 (0.85) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL12391076 | 0.92 | PSMB5 (0.84) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL22604863 | 0.91 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL253622 | 0.91 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL29454797 | 0.90 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL20694721 | 0.90 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826825 | 0.89 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826826 | 0.89 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4710 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748376-A2 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130990-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ULTRAGENYX PHARMACEUTICAL INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260128175-A1 | Methods and Systems for Analysis of Gene Expression Data | AMPEL BIOSOLUTIONS LLC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260117297-A1 | Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases | AMPEL BIOSOLUTIONS LLC (US) | 2026-04-30 | — | — | US | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| WO-2022031330-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS | CURIS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220041745-A1 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses | JANSSEN BIOTECH INC (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220041584-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022029782-A1 | LONG ACTING ANTICANCER COMPOSITIONS | INTRAGEL THERAPEUTICS LTD. (IL) | 2022-02-10 | — | — | WO | claimed |
| US-20220041742-A1 | Methods for Treating Multiple Myeloma | JANSSEN BIOTECH, INC. | 2022-02-10 | — | — | US | claimed |
| US-20220031840-A1 | Method of Treatment | HAEMALOGIX PTY LTD (AU) | 2022-02-03 | — | — | US | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | claimed |